Self-reported quality of life in symptomatic and asymptomatic women with X-linked adrenoleukodystrophy.
adrenoleukodystrophy (X-ALD)
heterozygote
myeloneuropathy
quality of life
women
Journal
Brain and behavior
ISSN: 2162-3279
Titre abrégé: Brain Behav
Pays: United States
ID NLM: 101570837
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
14
12
2022
accepted:
17
12
2022
pubmed:
8
2
2023
medline:
17
3
2023
entrez:
7
2
2023
Statut:
ppublish
Résumé
Up to 80% of women with X-linked adrenoleukodystrophy (X-ALD) develop symptoms of myelopathy and peripheral neuropathy during their lifetime. The study's objective was to compare symptomatic versus asymptomatic women with X-ALD regarding their physical and mental well-being and quality of life. Data were obtained from a prospective, international, cross-sectional cohort study of women with X-ALD recruited both clinically and population based. Symptoms, quality of life, and physical and mental co-morbidities were assessed by questionnaires. Women were considered symptomatic if they reported any sign of myelopathy or peripheral neuropathy. Group differences between symptomatic versus asymptomatic women and between age groups were examined using χ Complete data were available from N = 180 women (mean age: 51.2 ± 13.6 years, range: 18-85), of whom 71.7% were classified as symptomatic, with prevalence increasing with age. Symptomatic versus asymptomatic women reported poorer physical and mental health, with 26.4% meeting the criteria for a clinical depression, 73.6% reporting chronic pain, 80.6% sleeping disturbances, 38.2% sexual dysfunction, and 47.3% restless legs syndrome. Large group differences were found on the physical health, but not on the mental health component of quality of life, where symptomatic women only differed when controlling for having a boy affected by X-ALD (small effect) and treatment frequency (medium effect). Symptomatic women with X-ALD present with physical and psychological co-morbidities significantly reducing individuals' quality of life. The findings emphasize the need to develop new multi-disciplinary treatment options tailored to women's specific needs.
Sections du résumé
BACKGROUND
Up to 80% of women with X-linked adrenoleukodystrophy (X-ALD) develop symptoms of myelopathy and peripheral neuropathy during their lifetime. The study's objective was to compare symptomatic versus asymptomatic women with X-ALD regarding their physical and mental well-being and quality of life.
METHODS
Data were obtained from a prospective, international, cross-sectional cohort study of women with X-ALD recruited both clinically and population based. Symptoms, quality of life, and physical and mental co-morbidities were assessed by questionnaires. Women were considered symptomatic if they reported any sign of myelopathy or peripheral neuropathy. Group differences between symptomatic versus asymptomatic women and between age groups were examined using χ
RESULTS
Complete data were available from N = 180 women (mean age: 51.2 ± 13.6 years, range: 18-85), of whom 71.7% were classified as symptomatic, with prevalence increasing with age. Symptomatic versus asymptomatic women reported poorer physical and mental health, with 26.4% meeting the criteria for a clinical depression, 73.6% reporting chronic pain, 80.6% sleeping disturbances, 38.2% sexual dysfunction, and 47.3% restless legs syndrome. Large group differences were found on the physical health, but not on the mental health component of quality of life, where symptomatic women only differed when controlling for having a boy affected by X-ALD (small effect) and treatment frequency (medium effect).
CONCLUSIONS
Symptomatic women with X-ALD present with physical and psychological co-morbidities significantly reducing individuals' quality of life. The findings emphasize the need to develop new multi-disciplinary treatment options tailored to women's specific needs.
Identifiants
pubmed: 36748403
doi: 10.1002/brb3.2878
pmc: PMC10013936
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2878Subventions
Organisme : European Leukodystrophy Association (ELA) International
ID : ELA 2020-P001
Informations de copyright
© 2023 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
Références
Genet Med. 2021 May;23(5):837-844
pubmed: 33420343
Sex Med Rev. 2016 Jul;4(3):197-212
pubmed: 27871953
Dtsch Arztebl Int. 2020 Sep 25;117(39):653-658
pubmed: 33357346
Int J Dev Neurosci. 2020 Feb;80(1):52-72
pubmed: 31909500
Curr Med Res Opin. 2008 Jan;24(1):307-17
pubmed: 18070379
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3130-9
pubmed: 11124729
Endocr Rev. 2020 Aug 1;41(4):
pubmed: 32364223
Brain Behav. 2023 Mar;13(3):e2878
pubmed: 36748403
Nat Rev Neurol. 2018 Feb;14(2):94-105
pubmed: 29302065
Ann Acad Med Singap. 1994 Mar;23(2):129-38
pubmed: 8080219
Sleep Med. 2022 Mar;91:31-34
pubmed: 35245789
Brain Dev. 2008 Aug;30(7):477-82
pubmed: 18430533
Lancet Public Health. 2021 Oct;6(10):e729-e738
pubmed: 33961802
JAMA Netw Open. 2020 Jan 3;3(1):e1920356
pubmed: 32003821
J Neurol. 2011 Feb;258(2):323-4
pubmed: 20803344
J Neurol Neurosurg Psychiatry. 2019 May;90(5):543-554
pubmed: 30467211
Int J Neonatal Screen. 2021 Apr 17;7(2):
pubmed: 33920672
Eur Neurol. 1993;33(5):390-2
pubmed: 8243517
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
J Nerv Ment Dis. 2012 May;200(5):401-5
pubmed: 22551793
J Sex Marital Ther. 2005 Jan-Feb;31(1):1-20
pubmed: 15841702
Pain Ther. 2021 Jun;10(1):505-523
pubmed: 33609269
Arch Intern Med. 2005 Jun 13;165(11):1286-92
pubmed: 15956009
Sleep Med Rev. 2012 Aug;16(4):283-95
pubmed: 21795081
Int J Environ Res Public Health. 2021 May 08;18(9):
pubmed: 34066738
Nat Rev Endocrinol. 2016 Oct;12(10):606-15
pubmed: 27312864
J Psychiatr Res. 2012 Apr;46(4):444-50
pubmed: 22265888
Sleep Med. 2017 Feb;30:57-63
pubmed: 28215264
Sleep Med. 2003 Mar;4(2):121-32
pubmed: 14592342
NCHS Data Brief. 2020 Nov;(390):1-8
pubmed: 33151145
Eur J Neurol. 2020 Nov;27(11):e73
pubmed: 32367612
J Affect Disord. 2010 Jun;123(1-3):108-15
pubmed: 19892406
Int J MS Care. 2013 Spring;15(1):15-20
pubmed: 24453758
Prev Chronic Dis. 2015 Mar 19;12:E38
pubmed: 25789499
BMC Fam Pract. 2016 Jul 21;17:88
pubmed: 27439905
Eur J Neurol. 2019 Feb;26(2):326-332
pubmed: 30295399
Brain. 2014 Mar;137(Pt 3):693-706
pubmed: 24480483
MMWR Surveill Summ. 2022 Jan 07;71(1):1-19
pubmed: 34990443
Orphanet J Rare Dis. 2019 Feb 7;14(1):30
pubmed: 30732635
Ann Neurol. 2021 Aug;90(2):266-273
pubmed: 34105176
J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208
pubmed: 10782451
Pain. 2018 Nov;159(11):2394-2402
pubmed: 30028790
JIMD Rep. 2015;22:77-83
pubmed: 25763509
Eur J Med Genet. 2020 Dec;63(12):104062
pubmed: 32931946
Mult Scler Relat Disord. 2020 Nov;46:102576
pubmed: 33296974
Metab Brain Dis. 2015 Oct;30(5):1279-84
pubmed: 25920484
Mol Genet Metab Rep. 2021 Aug 31;29:100795
pubmed: 34504770
JAMA. 1999 Feb 10;281(6):537-44
pubmed: 10022110
Orphanet J Rare Dis. 2012 Aug 13;7:51
pubmed: 22889154
Orphanet J Rare Dis. 2021 Jan 6;16(1):14
pubmed: 33407709
BMC Psychiatry. 2017 Dec 4;17(1):389
pubmed: 29202737